Antibody Optimization Services

Yes. We can combine multiple goals—such as affinity, developability, stability, and manufacturability—within one optimization program, with a clear prioritization strategy based on your end use and constraints.

You’re guided by a dedicated PhD-level scientist, who will recommend the most efficient path based on your antibody, your target product profile, and your constraints (timeline, budget, format, assay availability, regulatory stage, etc.).

Yes. AI-driven designs are always experimentally validated within the workflow to confirm that the selected variants deliver the intended performance improvements.

Our proprietary AI is designed with this exact risk in mind: improving developability without compromising function. For example, our AI-driven humanization workflow includes a developability checkpoint to help ensure the humanized antibody maintains performance.

Learn more about our Antibody Humanization Service

Yes. Developability considerations are integrated into our optimization strategy. As an example, our AI-driven humanization workflow includes a developability check to help ensure the final candidates maintain performance and remain suitable for downstream development.

Learn more about our Antibody Humanization Service

Yes. We can carry optimized candidates directly into downstream steps such as transient expression for rapid material generation and stable cell line development for long-term production.

Our AI optimization services achieve >85% success overall, with an outstanding 100% success rate for humanization.

No. Your optimized sequences and variants are IP-free—there are no licensing fees or usage restrictions tied to the AI-generated outputs.

Yes. We can integrate optimization into a broader program that includes antibody engineering services and production through transient expression or stable cell line development, depending on your needs.